Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00520741 · ClinicalTrials.gov registry record · Phase 3
Trial to Demonstrate the Efficacy and Safety of Conversion to Lacosamide Monotherapy for Partial-onset Seizures
A Phase 3 study of Epilepsy, sponsored by UCB Biosciences.
- Completed
- Registry status
- Phase 3
- Development phase
- 426
- Enrollment target
- 20
- Study locations
NCT00520741 is a Phase 3 study of Epilepsy that has completed, run by UCB Biosciences. The registered enrollment target is 426 participants, below the 950-participant average among 160 other Epilepsy trials with a reported enrollment target (55% lower). The trial reports 20 study locations across 5 states.
The verdict
NCT00520741, a Phase 3 study of Epilepsy, has completed, sponsored by UCB Biosciences.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 426 participants
- Enrollment target
- 20
- Study locations
Study Summary
The objective of this historical-controlled trial is to demonstrate the efficacy and safety of conversion to Lacosamide monotherapy in subjects with Partial-onset Seizures who are withdrawn from 1 to 2 marketed antiepileptic drugs.
Conditions Studied
Interventions
- DRUG Lacosamide
Study Locations (20)
California
- 120 - La Habra
- 156 - Loma Linda
- 59 - Los Angeles
- 76 - Los Angeles
- 45 - Newport Beach
- 21 - Santa Monica
- 107 - Torrance
Arizona
- 14 - Phoenix
- 151 - Phoenix
- 9 - Phoenix
- 150 - Sun City
- 103 - Tucson
Alabama
- 48 - Alabaster
- 10 - Birmingham
- 18 - Huntsville
- 42 - Northport
Arkansas
- 102 - Jonesboro
- 7 - Little Rock
- 86 - Little Rock
Colorado
- 60 - Aurora
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 426 participants |
| Start Date | 2007-08 |
| Est. Completion | 2012-12 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00520741
The ClinicalTrials.gov registry entry for NCT00520741 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 426 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 950-participant average among 160 other Epilepsy trials with a reported enrollment target (55% lower). The listed sponsor is UCB Biosciences, which has 39 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Epilepsy appearing as the primary indexed condition, and to 1 intervention - of which Lacosamide is the first listed.
NCT00520741 reports 20 study locations spanning 5 distinct geographic areas - top geographies include California, Arizona, Alabama.
Frequently Asked Questions
What is clinical trial NCT00520741 about?
NCT00520741 is a clinical study titled "Trial to Demonstrate the Efficacy and Safety of Conversion to Lacosamide Monotherapy for Partial-onset Seizures". The objective of this historical-controlled trial is to demonstrate the efficacy and safety of conversion to Lacosamide monotherapy in subjects with Partial-onset Seizures who are withdrawn from 1 to 2 marketed antiepileptic drugs.
What is the current status of trial NCT00520741?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 426 participants. The study started on 2007-08. Estimated completion is 2012-12.
What conditions does trial NCT00520741 study?
This clinical trial studies the following conditions: Epilepsy.
What interventions are being tested in trial NCT00520741?
The interventions under investigation include: Lacosamide (DRUG).
Who is sponsoring clinical trial NCT00520741?
This trial is sponsored by UCB Biosciences, which has 39 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00520741 being conducted?
This trial has 20 study locations across Alabama, Arizona, Arkansas, California, Colorado. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Epilepsy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Test the Safety and Tolerability of Brivaracetam in Children and Adolescents With Seizures
RECRUITING · Phase 3
-
Lemborexant Treatment of Insomnia Linked to Epilepsy
RECRUITING · Phase 3
-
RNS System NAUTILUS Study
ACTIVE NOT RECRUITING · Phase 3
-
A Study to Investigate the Efficacy and Safety of Cannabidiol (GWP42003-P; CBD) as Adjunctive Treatment for Seizures Associated With Lennox-Gastaut Syndrome in Children and Adults
COMPLETED · Phase 3
-
Clobazam in Patients With Lennox-Gastaut Syndrome
COMPLETED · Phase 3
-
Pediatric Epilepsy Study
COMPLETED · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.